Ruxolitinib for Polycythemia Vera Intolerant or Resistant to Hydroxyurea : Episode 2

The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance

May 1, 2024

Opinion

Video

Gabriela Hobbs, MD, provides an overview of the role of ruxolitinib in treating patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.

EP: 1.Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera

Now Viewing

EP: 2.The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance

EP: 3.Objectives and Study Design of MAJIC-PV

EP: 4.Inside MAJIC-PV: A Closer Look at the Patient Population

EP: 5.Key Findings from MAJIC-PV

EP: 6.Safety Analysis and Interpreting Results from MAJIC-PV

EP: 7.Key Takeaways Following MAJIC-PV

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!